{"data":[{"accessionNo":"0002012383-26-003872","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":23211736,"percentOfClass":6.7,"filedAt":"2026-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001999371-26-021654","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-09-28","reportingPerson":"TPG GP A, LLC","reportingCik":"0001903793","personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-30","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001999371-26-021654","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-09-28","reportingPerson":"James G. Coulter","reportingCik":"0001099776","personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-30","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001999371-26-021654","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-09-28","reportingPerson":"Jon Winkelried","reportingCik":"0001366946","personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-09-30","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Frazier Life Sciences Public Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":19445046,"percentOfClass":5.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"FHMLSP, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":19445046,"percentOfClass":5.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"FHMLSP, L.P.","reportingCik":null,"personType":"PN","sharesOwned":19445046,"percentOfClass":5.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"FHMLS XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1941465,"percentOfClass":0.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Frazier Life Sciences XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1941465,"percentOfClass":0.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"FHMLS XII, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":1941465,"percentOfClass":0.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"FHMLS XI, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":753251,"percentOfClass":0.2,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Frazier Life Sciences XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":753251,"percentOfClass":0.2,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"FHMLS XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":753251,"percentOfClass":0.2,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"James N. Topper","reportingCik":null,"personType":"IN","sharesOwned":306906,"percentOfClass":0.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Frazier Life Sciences X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":306906,"percentOfClass":0.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Patrick J. Heron","reportingCik":null,"personType":"IN","sharesOwned":306906,"percentOfClass":0.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"FHMLS X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":306906,"percentOfClass":0.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"FHMLS X, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":306906,"percentOfClass":0.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0000093751-26-000405","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"ALLOGENE THERAPEUTICS INC","ticker":"ALLO","cusip":"019770106","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":19025826,"percentOfClass":5.5,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":11,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Arie Belldegrun, M.D.","reportingCik":null,"personType":"IN","sharesOwned":13610578,"percentOfClass":3.9,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":11,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Bellco Legacy IV LLC","reportingCik":null,"personType":"OO","sharesOwned":4710120,"percentOfClass":1.3,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":11,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Vida Ventures LLC","reportingCik":null,"personType":"OO","sharesOwned":1798163,"percentOfClass":0.5,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":11,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Vida Ventures III, L.P.","reportingCik":null,"personType":"OO","sharesOwned":1720172,"percentOfClass":0.5,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":11,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Bellco Legacy LLC","reportingCik":null,"personType":"OO","sharesOwned":539867,"percentOfClass":0.2,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":11,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Vida Ventures III-A, L.P.","reportingCik":null,"personType":"OO","sharesOwned":3965,"percentOfClass":0,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001104659-26-062730","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Kenneth Griffin","reportingCik":null,"personType":"HC,IN","sharesOwned":6855120,"percentOfClass":2.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001104659-26-062730","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel Advisors LLC","reportingCik":null,"personType":"IA,HC,OO","sharesOwned":5795242,"percentOfClass":2.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001104659-26-062730","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel Advisors Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":5795242,"percentOfClass":2.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001104659-26-062730","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":5795242,"percentOfClass":2.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001104659-26-062730","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel Securities GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":1059878,"percentOfClass":0.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001104659-26-062730","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel Securities Group LP","reportingCik":null,"personType":"HC,PN","sharesOwned":1059878,"percentOfClass":0.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001104659-26-062730","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Citadel Securities LLC","reportingCik":null,"personType":"BD,OO","sharesOwned":614069,"percentOfClass":0.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0000902664-26-002534","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Weston Nichols","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0000902664-26-002534","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Lynx1 Capital Management LP","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000006","formType":"SCHEDULE 13G/A","amendmentNo":10,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Arie Belldegrun, M.D.","reportingCik":null,"personType":"IN","sharesOwned":13466383,"percentOfClass":5.4,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-26-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"David D. Chang, M.D., Ph.D.","reportingCik":null,"personType":"IN","sharesOwned":12297354,"percentOfClass":4.9,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000006","formType":"SCHEDULE 13G/A","amendmentNo":10,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Bellco Legacy IV LLC","reportingCik":null,"personType":"OO","sharesOwned":4710120,"percentOfClass":1.9,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000006","formType":"SCHEDULE 13G/A","amendmentNo":10,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vida Ventures III, L.P.","reportingCik":null,"personType":"OO","sharesOwned":1720172,"percentOfClass":0.7,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000006","formType":"SCHEDULE 13G/A","amendmentNo":10,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vida Ventures LLC","reportingCik":null,"personType":"OO","sharesOwned":1798163,"percentOfClass":0.7,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-26-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Chang 2006 Family Trust","reportingCik":null,"personType":"OO","sharesOwned":1201108,"percentOfClass":0.5,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-26-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"JEC 2019 Trust","reportingCik":null,"personType":"OO","sharesOwned":856044,"percentOfClass":0.3,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-26-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"RTC 2019 Trust","reportingCik":null,"personType":"OO","sharesOwned":856044,"percentOfClass":0.3,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000006","formType":"SCHEDULE 13G/A","amendmentNo":10,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Bellco Legacy LLC","reportingCik":null,"personType":"OO","sharesOwned":539867,"percentOfClass":0.2,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000006","formType":"SCHEDULE 13G/A","amendmentNo":10,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vida Ventures III-A, L.P.","reportingCik":null,"personType":"OO","sharesOwned":3965,"percentOfClass":0,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"Frazier Life Sciences Public Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":16205306,"percentOfClass":4.7,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"FHMLSP, L.P.","reportingCik":null,"personType":"PN","sharesOwned":16205306,"percentOfClass":4.7,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"FHMLSP, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":16205306,"percentOfClass":4.7,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"FHMLS XII, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":1561500,"percentOfClass":0.5,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"Frazier Life Sciences XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1561500,"percentOfClass":0.5,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"FHMLS XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1561500,"percentOfClass":0.5,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"FHMLS XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":722956,"percentOfClass":0.2,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"FHMLS XI, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":722956,"percentOfClass":0.2,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"Frazier Life Sciences XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":722956,"percentOfClass":0.2,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"Frazier Life Sciences X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":306906,"percentOfClass":0.1,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"FHMLS X, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":306906,"percentOfClass":0.1,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"James N. Topper","reportingCik":null,"personType":"IN","sharesOwned":306906,"percentOfClass":0.1,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"Patrick J. Heron","reportingCik":null,"personType":"IN","sharesOwned":306906,"percentOfClass":0.1,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001231919-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":"019770106","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-04-16","reportingPerson":"FHMLS X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":306906,"percentOfClass":0.1,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Arie Belldegrun, M.D.","reportingCik":null,"personType":"IN","sharesOwned":13248170,"percentOfClass":5.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Bellco Legacy IV LLC","reportingCik":null,"personType":"OO","sharesOwned":4710120,"percentOfClass":2.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Vida Ventures III, L.P.","reportingCik":null,"personType":"OO","sharesOwned":1720172,"percentOfClass":0.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Vida Ventures LLC","reportingCik":null,"personType":"OO","sharesOwned":1798163,"percentOfClass":0.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Bellco Legacy LLC","reportingCik":null,"personType":"OO","sharesOwned":539867,"percentOfClass":0.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Vida Ventures III-A, L.P.","reportingCik":null,"personType":"OO","sharesOwned":3965,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0000078003-26-000022","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share (the \"Common Stock\")","eventDate":"2025-11-06","reportingPerson":"Pfizer Inc.","reportingCik":"0000078003","personType":"CO","sharesOwned":22032040,"percentOfClass":9,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-26-000002","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"David D. Chang, M.D., Ph.D.","reportingCik":null,"personType":"IN","sharesOwned":12101223,"percentOfClass":5.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-26-000002","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Chang 2006 Family Trust","reportingCik":null,"personType":"OO","sharesOwned":1201108,"percentOfClass":0.5,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-26-000002","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"RTC 2019 Trust","reportingCik":null,"personType":"OO","sharesOwned":856044,"percentOfClass":0.4,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-26-000002","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"JEC 2019 Trust","reportingCik":null,"personType":"OO","sharesOwned":856044,"percentOfClass":0.4,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Arie Belldegrun, M.D.","reportingCik":null,"personType":"IN","sharesOwned":12668344,"percentOfClass":5.6,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Bellco Legacy IV LLC","reportingCik":null,"personType":"OO","sharesOwned":4710120,"percentOfClass":2.1,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Vida Ventures III, L.P.","reportingCik":null,"personType":"OO","sharesOwned":1720172,"percentOfClass":0.8,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Vida Ventures LLC","reportingCik":null,"personType":"OO","sharesOwned":1798163,"percentOfClass":0.8,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Bellco Legacy LLC","reportingCik":null,"personType":"OO","sharesOwned":539867,"percentOfClass":0.2,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001296549-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Vida Ventures III-A, L.P.","reportingCik":null,"personType":"OO","sharesOwned":3965,"percentOfClass":0,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001422849-25-000094","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Capital World Investors","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"David D. Chang, M.D., Ph.D.","reportingCik":null,"personType":"IN","sharesOwned":11234918,"percentOfClass":4.9,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Chang 2006 Family Trust","reportingCik":null,"personType":"OO","sharesOwned":1201108,"percentOfClass":0.5,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"RTC 2019 Trust","reportingCik":null,"personType":"OO","sharesOwned":856044,"percentOfClass":0.4,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/allo"},{"accessionNo":"0001611024-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001737287","issuerName":"Allogene Therapeutics, Inc.","ticker":"ALLO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"JEC 2019 Trust","reportingCik":null,"personType":"OO","sharesOwned":856044,"percentOfClass":0.4,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/allo"}],"updatedAt":"2026-11-04T01:31:17.295Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/allo","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}